Shots:
- The P-IIIb (STEP UP) study assessed semaglutide (7.2mg) vs semaglutide (2.4mg) & PBO as an adjunct to lifestyle intervention in obese adults (n=1,407; BMI ≥30kg/m^2) without diabetes for 72wks. STEP program also includes STEP UP T2D study of semaglutide (7.2mg) in obese adults (n=512) with T2D for 72wks.
- Study met its 1EP, depicting superior weight loss of 20.7% (7.2mg) vs 17.5% (2.4mg) & 2.4% (PBO) as well as 33.2% vs 16.7% & 0% had a weight loss of 25% or more after 72wks. With the treatment policy estimand, weight losses were 18.7% vs 15.6% & 3.9%
- Full findings from the STEP UP study will be featured at future conferences while the results from STEP UP T2D trial are anticipated within the next few months
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk Expands its Partnership with Valo Health to Discover and Develop Novel Therapies for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
